RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.

Slides:



Advertisements
Similar presentations
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Advertisements

Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Efficacy and Safety.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Professor Abdus Samad MD FACC Karachi Institute of Heart Diseases Karachi, Pakistan May 1, 2010.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
A few basics of cardiac surgery…. Brett Sheridan, MD Assistant Professor Department of Surgery.
CABG GUIDELINES SANJAY DRAVID, M.D.. INTRODUCTION ACC/AHA GUIDELINE UPDATE FOR CORONARY ARTERY BYPASS GRAFT SURGERY (JACC 2004; 44: AND CIRCULATION.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
PCI VS CABG JOURNAL REVIEW
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Clinical Outcomes with Newer Antihyperglycemic Agents
REVASCULARIZATION Vs MEDICAL THERAPY IN STABLE CAD
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36.
VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
RITA-3 ESC 4 th September 2005 The impact of underlying risk and gender on the benefit of early intervention in non-ST elevation acute coronary syndrome.
Journal Club Jeffrey P Schaefer, MD April 16, 2007.
Antiplatelet Interventions in Acute Coronary Syndromes.
4S: Scandinavian Simvastatin Survival Study
MICHELANGELO: OASIS 5 Women’s Substudy Dr. Eva Swahn Department of Cardiology, Heart Centre, University Hospital, Linköping Sweden Disclosure Funded by.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Atorvastatin Versus Revascularization Treatments (AVERT) Trial Presented at The American Heart Association Scientific Sessions 1998 Presented by Dr. Bertram.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
The Benefit of an Invasive Strategy in Women Versus Men with Non-ST-Elevation ACS: A Collaborative Meta-Analysis of Randomized Trials Michelle O’Donoghue,
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.
Survival Benefits in Higher Risk Patients Coronary Revascularization has Revolutionized the Therapy of Ischemic Heart Disease Acute coronary syndromes.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Prognosis of Patients With LV Dysfunction and CAD
Total Occlusion Study of Canada (TOSCA-2) Trial
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
William E. Boden, MD, FACC, FAHA
Revascularization in Patients With Left Ventricular Dysfunction:
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Clinical need for determination of vulnerable plaques
Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.
Section 5: Intervention and drug therapy
American College of Cardiology Presented by Dr. Stephan Windecker
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
3-Year Clinical Outcomes From the RESOLUTE US Study
Preventive Angioplasty in Myocardial Infarction Trial
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
The European Society of Cardiology Presented by RJ De Winter
O.L.Reuchlin gebruik van CT binnen de cardiogie
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology University & Royal Infirmary Edinburgh

Conflicts of interest slide Advanced angioplasty 2008 Device industry: None Grant Funding: British Heart Foundation, Wellcome Trust, Medical Research Council, ESC, Sanofi-Aventis, BMS, GSK Travel & honoraria: Sanofi-Aventis, BMS, GSK

Event Rates: “Primary Prevention”; Stable Angina ; non-ST Elevation ACS. Death / MI after 12 months Wallentin L et al. Lancet 2000;356:9–16 Juul-Moller S et al. Lancet 1992;340:1421–1425 Shepherd J et al. N Engl J Med 1995;333:1301–1307 Poole-Wilson et al ACTION Lancet 2004;364: Death/ MI (%) Months of follow up Unstable angina/non Q wave MI (FRISC II) Stable angina (SAPAT) Primary Prevention (WOSCOPS) ACTION trial (stable CAD) Approx 1.5% Stable CAD

salvage of ischaemic myocardium Stable anginaNon-ST elevation ACSST Elevation MI Concepts: Extent of salvage (infarction) proportional to clinical benefit: death or MI Extent of reversible ischaemia proportional to benefit on relief of angina

Conservative Intervention Cumulative percentage Follow-up time (years) RITA 3, 5 yr outcome: p = odds ratio: % CI % 12.1% Cardiovascular Deaths: p = odds ratio: % CI 0.49 – 0.95 Lancet 2005: 366; Death or MI: odds ratio 0.78, 95%CI , p= 0.04 All deaths BHF RITA-3

Conservative Follow-up time (years) Cumulative risk of death or MI by risk score and treatment group Intervention Fox KAA Lancet 2005, 366: BHF RITA-3

PCI vs. Conservative Therapy: Stable CAD Meta-analysis (pre-COURAGE)  Primary Endpoint: Death, or nonfatal MI, CABG, and PCI during follow- up (in the target vessel or other vessel/segment). PCIn=1476PCIn=1476 Conservative Therapy n=1474 n=1474 Stable CAD & >1 stenosis: 2950 patients from randomized trials (PCI versus conservative medical therapy) Katritsis DG et al Circulation 2005; 111:

PCI vs. Conservative Therapy: Meta-Analysis No significant difference: death, cardiac death or MI, nonfatal MI, and need for CABGNo significant difference: death, cardiac death or MI, nonfatal MI, and need for CABG # patients Katritsis DG et al Circulation 2005; 111:

Stable CAD: PCI vs Conservative Medical Management Meta-analysis of 11 randomized trials; N = 2,950 Death Cardiac death or MI Nonfatal MI CABG PCI Katritsis DG et al. Circulation. 2005;111: P Risk ratio (95% Cl) Favours PCI Favours Medical Management

The 95% confidence intervals excluded relative risk differences of 28%.The 95% confidence intervals excluded relative risk differences of 28%. PCI vs. Conservative Therapy: Death Katritsis DG et al Circulation 2005; 111:

RITA-2: PTCA vs Medical Therapy in Stable Angina(n=1000) PTCAMedicalORP Death/MI 32 (6.3%) 17 (3.3%) CABG 40 (7.2%) 30 (5.8%) Post-rand PTCA 62 (12.3%) 101 (19.9%) Any PTCA 533 (>100.0%) 101 (19.9%) 5.28<< Total procedures << Lancet 1997

RITA-2: Impact on Grade 2 Angina (Med v PTCA) RITA-2 Lancet 1997

RITA 2: Quality of Life over 3 years of Follow-up Pocock et al. JACC 2000

Compared with conservative therapy, PCI does not decrease mortality or the risk of MI during follow-up in patients with chronic CAD. Compared with conservative therapy, PCI does not decrease mortality or the risk of MI during follow-up in patients with chronic CAD. A trend for increased risk of MI in patients undergoing PCI was observed. A trend for increased risk of MI in patients undergoing PCI was observed. Even when analyses were limited to studies that used stents, the meta-analysis found no evidence of superiority for the PCI strategy. Even when analyses were limited to studies that used stents, the meta-analysis found no evidence of superiority for the PCI strategy. Need for more randomized trials… Need for more randomized trials… Compared with conservative therapy, PCI does not decrease mortality or the risk of MI during follow-up in patients with chronic CAD. Compared with conservative therapy, PCI does not decrease mortality or the risk of MI during follow-up in patients with chronic CAD. A trend for increased risk of MI in patients undergoing PCI was observed. A trend for increased risk of MI in patients undergoing PCI was observed. Even when analyses were limited to studies that used stents, the meta-analysis found no evidence of superiority for the PCI strategy. Even when analyses were limited to studies that used stents, the meta-analysis found no evidence of superiority for the PCI strategy. Need for more randomized trials… Need for more randomized trials… PCI vs. Conservative Therapy: Summary Katritsis DG et al Circulation 2005; 111:

objective evidence of myocardial ischemia objective evidence of myocardial ischemia stenosis > 70% in > one proximal coronary artery stenosis > 70% in > one proximal coronary artery Objective myocardial ischemia: ST-segment depression or T-wave inversion on the resting ECG or inducible ischemia (exercise or vasodilator stress) or at least one coronary stenosis > 80% plus classic angina BMS not DES; all patients suitable for PCI; low event rate 2287 patients “Optimal Medical Therapy“ At 5 yrs: 70% had LDL <2.20 mmol per liter) 65% and 94% had systolic and diastolic BP < 130/85 45% of patients with diabetes had Hb A1c <7% High adherence to diet, exercise, and smoking cessation

COURAGE: Freedom from angina Boden WE et al. N Engl J Med Yr (follow-up) PCI (%) Medical therapy (%) p Baseline1213NS 16658< NS

Boden WE et al. N Engl J Med COURAGE: Cumulative event rates (4.6 yrs) Outcome PCI (%) Medical Rx (%) Hazard ratio 95% CI p Death, MI –

Boden WE et al. N Engl J Med COURAGE: Cumulative event rates (4.6 yrs) Outcome PCI (%) Medical Rx (%) Hazard ratio 95% CI p Death, MI – Death, MI, stroke – Death – Nonfatal MI – Stroke – Hospitalization for ACS – Revascularization (PCI or CABG) –0.71<0.001

Rest Mid Base Apex StressRestStress After optimal anti-ischemic medical therapy Before treatment COURAGE study Patient randomized to medical treatment only Case presented at ACC 2003 by Dr. Robert O´Rourke

PCI in stable angina… Event rates of death & MI approx 1.5% per annum - on optimal medical therapy Scope to improve rate of death or MI is very limited - even in patients with proximal stenosis & inducible ischaemia PCI is superior to medical therapy (at least over 3 yrs) in relief of angina, but not longer term Greater benefit in those with more extensive ischaemia (>5% LV) Role of PCI in those with angina and LV dysfunction is unresolved Conclusions: 2008